Zydus Lifesciences has announced another extension for its planned acquisition of Sterling Biotech Limited's (SBL) Active Pharmaceutical Ingredients (API) business. The company has now extended the closing date to June 30, 2026, marking the second extension since the original agreement was signed.

Timeline of Extensions

The acquisition timeline has seen multiple adjustments since the initial agreement. The following table outlines the progression of deadlines:

Reasons for Latest Extension

According to the company's latest regulatory filing dated December 24, 2025, Sterling Biotech is still working to complete certain conditions precedent outlined in the Business Transfer Agreement. Zydus Lifesciences stated that "SBL is still in the process of completing certain conditions precedents of the BTA and hence the Company and SBL have executed a letter to extend the closing date by June 30, 2026."

Transaction Details

The acquisition involves Sterling Biotech's API business, which represents a strategic expansion for Zydus Lifesciences in the pharmaceutical ingredients sector. The deal remains subject to the completion of various conditions precedent as specified in the original Business Transfer Agreement.

Regulatory Compliance

The company has maintained transparency throughout the process, informing stock exchanges about each development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The latest update was communicated to both BSE Limited and National Stock Exchange of India Limited.

Strategic Outlook

Despite the extended timeline, Zydus Lifesciences remains committed to completing the acquisition. The company expressed confidence that "the transaction is expected to be completed on or before June 30, 2026." The repeated extensions suggest the complexity of fulfilling all prerequisite conditions while maintaining the strategic value of the deal for both parties involved.